Market Cap | 59.09M | P/E | - | EPS this Y | -29.70% | Ern Qtrly Grth | - |
Income | -18.95M | Forward P/E | -0.79 | EPS next Y | 45.80% | 50D Avg Chg | -3.00% |
Sales | 18.11M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -4.00% |
Dividend | N/A | Price/Book | 0.70 | EPS next 5Y | - | 52W High Chg | -36.00% |
Recommedations | 2.00 | Quick Ratio | 3.50 | Shares Outstanding | 44.16M | 52W Low Chg | 50.00% |
Insider Own | 4.19% | ROA | -11.06% | Shares Float | 12.71M | Beta | 0.52 |
Inst Own | 27.85% | ROE | -24.66% | Shares Shorted/Prior | 15.08K/13.69K | Price | 1.35 |
Gross Margin | 100.00% | Profit Margin | -104.61% | Avg. Volume | 25,998 | Target Price | 12.00 |
Oper. Margin | -2,288.81% | Earnings Date | Mar 28 | Volume | 18,678 | Change | -1.46% |
Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a v POWERbody, which is in preclinical stage for the treatment off-tumor toxicities, as well as develops anti-CD28 bispecific POWERbody TCEs. The company was incorporated in 2011 and is headquartered in Suzhou, China.
HC Wainwright & Co. | Buy | Oct 4, 23 |
HC Wainwright & Co. | Buy | Sep 1, 23 |
HC Wainwright & Co. | Buy | Apr 21, 23 |
HC Wainwright & Co. | Buy | Mar 29, 23 |
HC Wainwright & Co. | Buy | Mar 21, 23 |
Morgan Stanley | Overweight | Jan 24, 23 |
HC Wainwright & Co. | Buy | Dec 7, 22 |
Morgan Stanley | Overweight | Sep 9, 22 |
Morgan Stanley | Overweight | Feb 1, 22 |